Taken together, our data from naïve BALB/c mice and TC-1 tumor-bearing C57BL/6 mice demonstrate that GPI-0100 is able to greatly enhance TA-CIN-specific CD4+, and E7-specific CD8+ T cell responses, and L2-specific neutralizing antibody titers in serum. This evidence concerns the gene CD4 and neoplasm.